menu
    • menu
    [{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enzene Biosciences \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Enzene Biosciences \/ Lupin Ltd"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Enzene Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ENZ215","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alkem Laboratories \/ Alkem Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Alkem Laboratories \/ Alkem Laboratories"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Enzene Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ENZ215","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alkem Laboratories \/ Alkem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alkem Laboratories \/ Alkem Laboratories"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkem Laboratories \/ Alkem Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Alkem Laboratories"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkem Laboratories \/ Alkem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alkem Laboratories \/ Alkem Laboratories"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"}]

    Find Clinical Drug Pipeline Developments & Deals by Alkem Laboratories

    Menu

    Alkem Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Empagliflozin,Linagliptin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkem Launches Generic Empagliflozin and Its Combinations in India Under ‘Empanorm’

                            Details : Empanorm L (empagliflozin-linagliptin) is an SGLT-2/DPP-4 inhibitor indicated for use in the treatment of type-2 diabetes mellitus, CKD and chronic heart failure (HF).

                            Product Name : Empanorm L

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 13, 2025

                            Lead Product(s) : Empagliflozin,Linagliptin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atexakin Alpha

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Sonnet BioTherapeutics

                            Deal Size : $2.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sonnet Partners with Alkem to Develop SON-080 For Diabetic Neuropathy

                            Details : Alkem to fund, develop and commercialize SON-080 for the treatment of DPN in India and commercialize SON-080 for the treatment of Chemotherapy Induced Neuropathy and Autonomic Neuropathy in India.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $1.0 million

                            September 10, 2024

                            Lead Product(s) : Atexakin Alpha

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Sonnet BioTherapeutics

                            Deal Size : $2.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alkem Inks Licensing Pact with Takeda to Introduce Vonoprazan in India

                            Details : The licensing deal will enhance Alkem's offerings in the gastrointestinal segment by including Vonzai (vonoprazan), a first-in-class potassium-competitive acid blocker.

                            Product Name : Vonzai

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 09, 2024

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enzene Biosciences Launches Bevacizumab

                            Details : Bevacizumab is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 29, 2023

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lupin Announces the Launch of Cetuximab

                            Details : Through collaboration, Lupin with Enzene will launch enz-124 (cetuximab) in India, the 1st biosimilar developed for Cetuximab, sold under the brand Erbitux. Cetuximab, a chimeric monoclonal antibody, is used as a targeted therapy for metastatic colorecta...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkem Subsidiary Enzene Launches Adalimumab Biosimilar in India

                            Details : Adalimumab-bwwd is being launched for treating autoimmune disease like rheumatoid arthritis and ankylosis spondylitis. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 23, 2023

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftazidime,Avibactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkem Becomes First Indian Company to Launch Novel Antibiotic for Multiple Drug Resistance (MDR) Infections

                            Details : Zidavi, which is a novel combination of ceftazidime and avibactam, a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae for pyelonephritis or Complicated Urinary Tract Infecti...

                            Product Name : Zidavi

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Ceftazidime,Avibactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENZ215

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Enzene Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : ENZ215

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Enzene Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Alkem Laboratories

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ENZ215

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Enzene Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimila...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 18, 2022

                            Lead Product(s) : ENZ215

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Enzene Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed

                            Enzene Biosciences

                            India arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab,Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Theramex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of T...

                            Details : Theramex has entered into an agreement with Enzene Biosciences to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab will be available in parenteral vials, subcutaneous prefilled s...

                            Product Name : RoActemra-Generic

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 23, 2021

                            Lead Product(s) : Tocilizumab,Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Theramex

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth